Epstein-Barr Virus Associated Lymphoma
3 clinical trials · Condition
◉ Watch Epstein-Barr Virus Associated Lymphoma
| Record | Firm | Date |
|---|---|---|
| An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas (NCT05011058) | Viracta Therapeutics, Inc. | 2021-05-28 |
| Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies (NCT03397706) | Viracta Therapeutics, Inc. | 2018-03-29 |
Track Epstein-Barr Virus Associated Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.